Plain-English translation of NCT05796375 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two new urine tests—the Xpert Bladder Cancer Monitor and the Bladder EpiCheck—can safely replace frequent cystoscopy (a camera procedure that looks inside the bladder) for monitoring early-stage bladder cancer. The study will compare three groups: people who receive frequent camera exams, people who receive urine tests with fewer camera exams, and people who receive a different urine test with fewer camera exams. The goal is to find a way to monitor your cancer that is less invasive and uncomfortable for you.
Current bladder cancer surveillance relies on frequent cystoscopy procedures, which can be uncomfortable, inconvenient, and affect quality of life. This trial aims to see whether simpler urine tests can detect cancer recurrence just as well while sparing patients from repeated invasive procedures.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of three groups for 2 years. If you're in the frequent cystoscopy group, you'll have camera exams of your bladder at 6, 12, 18, and 24 months. If you're in one of the urine test groups, you'll provide urine samples at 6 and 18 months and have doctor check-ups, with camera exams only at 12 and 24 months. Throughout the study, researchers will also ask about your quality of life, particularly how the surveillance methods affect your daily comfort and well-being.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
United States